An influenza virus seen through an electronic microscope. Credit: Sanofi Pasteur

The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) and awarded priority review designation to Roche’s baloxavir marboxil for the treatment of influenza.

Baloxavir marboxil is indicated as a single-dose, oral therapy for patients aged 12 years and above suffering from an acute, uncomplicated form of the infectious disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The investigational drug is formulated to act against the flu virus by blocking the cap-dependent endonuclease protein, which is present within the virus and is required for its replication.

Although Japanese pharmaceutical company Shionogi discovered baloxavir marboxil, Roche is developing the product globally under an agreement signed between the companies.

Roche Global Product Development chief medical officer and head Sandra Horning said: “The severity of the recent flu season underscores the need for new options beyond currently available treatments and, if approved, baloxavir marboxil would be the first flu medicine with a novel proposed mechanism of action in nearly 20 years.”

“If approved, baloxavir marboxil would be the first flu medicine with a novel proposed mechanism of action in nearly 20 years.”

The NDA submitted to the FDA includes data obtained during the Phase III CAPSTONE-1 clinical trial conducted to assess the efficacy and safety of twice daily baloxavir marboxil for five days in 1,436 US and Japanese flu patients who were otherwise healthy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the multi-centre, randomised, double-blind, placebo-controlled trial, baloxavir marboxil met both primary and secondary endpoints with a favourable tolerability profile.

The investigational candidate is being further evaluated in a Phase III development programme, which also includes paediatric populations with influenza.

Baloxavir marboxil is already approved in Japan to treat both paediatrics and adults with influenza types A and B.